Elanco Animal Health Incorporated (NYSE:ELAN) Holdings Trimmed by Integral Health Asset Management LLC

Integral Health Asset Management LLC trimmed its position in shares of Elanco Animal Health Incorporated (NYSE:ELAN) by 18.2% during the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 450,000 shares of the company’s stock after selling 100,000 shares during the period. Integral Health Asset Management LLC’s holdings in Elanco Animal Health were worth $6,494,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Benjamin F. Edwards & Company Inc. grew its holdings in shares of Elanco Animal Health by 337.7% during the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 1,764 shares of the company’s stock valued at $26,000 after acquiring an additional 1,361 shares in the last quarter. ORG Partners LLC purchased a new position in shares of Elanco Animal Health during the 2nd quarter valued at $31,000. nVerses Capital LLC purchased a new position in shares of Elanco Animal Health during the 2nd quarter valued at $32,000. Jones Financial Companies Lllp purchased a new position in shares of Elanco Animal Health during the 4th quarter valued at $37,000. Finally, Global Financial Private Client LLC purchased a new position in shares of Elanco Animal Health during the 1st quarter valued at $72,000. 97.48% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, Director Michael J. Harrington bought 3,500 shares of the business’s stock in a transaction on Thursday, August 22nd. The stock was purchased at an average price of $14.85 per share, with a total value of $51,975.00. Following the transaction, the director now directly owns 81,094 shares in the company, valued at $1,204,245.90. The acquisition was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In related news, Director Michael J. Harrington acquired 3,500 shares of the company’s stock in a transaction dated Thursday, August 22nd. The shares were bought at an average price of $14.85 per share, for a total transaction of $51,975.00. Following the acquisition, the director now owns 81,094 shares in the company, valued at approximately $1,204,245.90. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, CEO Jeffrey N. Simmons acquired 100,000 shares of the company’s stock in a transaction dated Monday, August 12th. The shares were bought at an average price of $13.01 per share, for a total transaction of $1,301,000.00. Following the acquisition, the chief executive officer now owns 145,000 shares in the company, valued at approximately $1,886,450. The disclosure for this purchase can be found here. Company insiders own 0.57% of the company’s stock.

Elanco Animal Health Stock Down 6.6 %

Elanco Animal Health stock opened at $14.07 on Monday. The firm has a market cap of $6.95 billion, a price-to-earnings ratio of -5.31, a P/E/G ratio of 1.44 and a beta of 1.40. The company has a debt-to-equity ratio of 0.92, a current ratio of 2.93 and a quick ratio of 1.75. Elanco Animal Health Incorporated has a fifty-two week low of $8.52 and a fifty-two week high of $18.80. The firm has a fifty day moving average price of $13.95 and a two-hundred day moving average price of $15.14.

Elanco Animal Health (NYSE:ELAN) last released its earnings results on Thursday, August 8th. The company reported $0.30 earnings per share for the quarter, topping analysts’ consensus estimates of $0.24 by $0.06. The firm had revenue of $1.18 billion during the quarter, compared to analyst estimates of $1.15 billion. Elanco Animal Health had a negative net margin of 27.94% and a positive return on equity of 7.29%. The business’s revenue was up 12.0% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.18 EPS. As a group, analysts forecast that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research firms have recently commented on ELAN. Morgan Stanley cut shares of Elanco Animal Health from an “overweight” rating to an “equal weight” rating and lowered their price target for the company from $17.00 to $15.00 in a report on Thursday. Barclays lowered their price target on shares of Elanco Animal Health from $23.00 to $21.00 and set an “overweight” rating on the stock in a report on Friday, June 28th. Piper Sandler lowered their price target on shares of Elanco Animal Health from $19.00 to $16.00 and set a “neutral” rating on the stock in a report on Monday, July 1st. Finally, Stifel Nicolaus reaffirmed a “buy” rating and issued a $20.00 price objective on shares of Elanco Animal Health in a research note on Thursday. One research analyst has rated the stock with a sell rating, two have issued a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $17.29.

Elanco Animal Health Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.